<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10019">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02976519</url>
  </required_header>
  <id_info>
    <org_study_id>1363.2</org_study_id>
    <secondary_id>2016-001504-31</secondary_id>
    <nct_id>NCT02976519</nct_id>
  </id_info>
  <brief_title>BI 443651 Multiple Rising Dose in Healthy Volunteers and COPD Subjects, Followed by a Cross-over in CF Subjects</brief_title>
  <official_title>A Phase Ib, Multicentre, Double Blind, Randomized, Two-part Study, First Part Multiple Rising Dose and Second Part Two-way Cross-over, to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of BI 443651 Compared to Placebo Via Respimat® in Healthy Volunteers, and COPD and CF Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of this study is to investigate the safety, tolerability, and pharmacokinetics
      of BI 443651 in male and female healthy volunteers and subjects with Chronic Obstructive
      Pulmonary Disease (COPD) or Cystic Fibrosis (CF).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2017</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (masked roles unspecified)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency (in percent) of subjects with treatment-emergent adverse events (TEAE) over the treatment period (Chronic obstructive pulmonary disease [COPD])</measure>
    <time_frame>up to 29 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency (in percent) of subjects with treatment-emergent adverse events (TEAE) over the treatment period (Cystic fibrosis [CF])</measure>
    <time_frame>up to 60 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency (in percent) of subjects with treatment-emergent adverse events (TEAE) over the treatment period (Healthy Volunteers [HV])</measure>
    <time_frame>up to 22 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>After the first dose on Day 1, AUC0-12 (area under the concentration-time curve of the analyte in plasma until 12 h after the first dose) (Healthy Volunteers)</measure>
    <time_frame>up to 12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>After the last dose on Day 7, Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval tau) (Healthy Volunteers)</measure>
    <time_frame>up to 156 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>After the last dose on Day 14, Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval tau) (Chronic obstructive pulmonary disease [COPD])</measure>
    <time_frame>up to 336 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>After the last dose on Day 14, Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval tau) (Cystic fibrosis [CF])</measure>
    <time_frame>up to 1200 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>After the first dose on Day 1, Cmax (maximum measured concentration of the analyte in plasma) (Healthy Volunteers [HV])</measure>
    <time_frame>up to 12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>After the first dose on Day 1, Cmax (maximum measured concentration of the analyte in plasma) (Chronic obstructive pulmonary disease [COPD])</measure>
    <time_frame>up to 12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>After the first dose on Day 1, Cmax (maximum measured concentration of the analyte in plasma) (Cystic fibrosis [CF])</measure>
    <time_frame>up to 12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>After the first dose on Day 1, AUC0-12 (area under the concentration-time curve of the analyte in plasma until 12 h after the first dose) (Chronic obstructive pulmonary disease [COPD])</measure>
    <time_frame>up to 12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>After the first dose on Day 1, AUC0-12 (area under the concentration-time curve of the analyte in plasma until 12 h after the first dose) (Cystic fibrosis [CF])</measure>
    <time_frame>up to 12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>After the last dose on Day 7, AUCtau,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval tau) (Healthy Volunteers)</measure>
    <time_frame>up to 156 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>After the last dose on Day 14, AUCtau,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval tau) (Chronic obstructive pulmonary disease [COPD])</measure>
    <time_frame>up to 336 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>After the last dose on Day 14, AUCtau,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval tau) (Cystic fibrosis [CF])</measure>
    <time_frame>up to 1200 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Cystic Fibrosis</condition>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>BI 443651</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 443651</intervention_name>
    <arm_group_label>BI 443651</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        Healthy volunteers:

          -  Signed informed consent

          -  Healthy male or female subjects

          -  Women of childbearing potential (WOCBP) should only be dosed after a confirmed
             menstrual period and/or with a progesterone level at Day-3 to Day-1

          -  Age of 18 to 55 years (incl.)

          -  Body mass index (BMI) of 18.5 to 32.0 kg/m2 (incl.)

          -  Forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) of equal
             or greater than 80% of predicted normal, at screening and prior to randomisation

        Chronic Obstructive Pulmonary Disease (COPD):

          -  Signed informed consent

          -  Males or females, with diagnosis of COPD

          -  Women of childbearing potential (WOCBP) should only be dosed after a confirmed
             menstrual period and/or with a progesterone level at Day -3 to Day -1

          -  Age 40 and 75 years (each inclusive)

          -  Body mass index (BMI) of 18.5 to 32.0 kg/m2 (incl.)

          -  Post-bronchodilator FEV1 =/&gt;50% of predicted normal value at screening

          -  Post-bronchodilator FEV1/FVC &lt;70% at screening

          -  Current or ex-smokers with a smoking history of more than 10 pack years

          -  Clinical stability as defined by stable respiratory medications, no evidence of acute
             upper/lower respiratory tract infection, no pulmonary exacerbation requiring use of
             intra-venous (i.v.)/oral antibiotics, or oral corticosteroids, any acute (serious or
             non-serious) illness not related to COPD

          -  Must be able to perform technically acceptable pulmonary function tests (PFTs).

        Cystic Fibrosis (Cross over part):

          -  Signed informed consent

          -  Males or females with a documented diagnosis of cystic fibrosis

          -  Women of childbearing potential (WOCBP) should only be dosed after a confirmed
             menstrual period and/or with a progesterone level at Day -3 to Day -1

          -  Age 18 to 55 years (each inclusive)

          -  BMI of 18 to 32.0 kg/m2 (incl.)

          -  Pre-bronchodilator FEV1 &gt;/= to 70% of predicted normal at screening and prior to
             randomisation

          -  Clinical stability as defined by no evidence of acute upper or lower respiratory
             tract infection; no pulmonary exacerbation requiring use of i.v. / oral / inhaled
             antibiotics, or oral corticosteroids; no change in pulmonary disease therapy; if on
             cycling antibiotics, these must be initiated within 2 weeks prior to randomisation;
             no acute (serious or non-serious) illness not related to cystic fibrosis; no
             infection with an organism associated with more rapid decline in pulmonary function
             (eg, Burkholderia cenocepacia, B dolosa, or Mycobacterium abscessus).

          -  Able to perform technically acceptable pulmonary functions test (PFTs)

          -  Further inclusion criteria apply.

        Exclusion criteria:

          -  Any evidence of a concomitant disease judged as clinically relevant by the
             investigator including gastrointestinal, hepatic, renal, respiratory*,
             cardiovascular, metabolic**, immunological, dermatologic, hematologic, neurological
             and psychiatric, oncological, coagulation or hormonal disorders as determined by
             medical history, examination, and clinical investigations at screening that may, in
             the opinion of the investigator, result in any of the following: Put the subject at
             risk because of participation in the study; Influence the results of the study; Cast
             doubt on the subject's ability to participate in the study (*except chronic
             obstructive pulmonary disease (COPD) and cystic fibrosis (CF) subjects; COPD subjects
             with resolved childhood asthma may be included; CF subjects may be included with
             concomitant asthma provided on stable medications for 6 weeks prior to inclusion into
             the study. Patients with acute bronchopulmonary aspergillosis may not be included. **
             CF subjects with diabetes are allowed to participate if their disease is under good
             control prior to screening as assessed by the principal investigator)

          -  Chronic or relevant acute infections.

          -  History of relevant orthostatic hypotension, fainting spells, or blackouts

          -  History of myocardial infarction; history of acute coronary syndrome

          -  History of and/or active life-threatening cardiac arrhythmia, as assessed by the
             investigator

          -  Major surgery (major according to the investigator's assessment)

          -  History of chronic kidney disease (estimate glomerular filtration rate (EGFR) &lt;59
             mls/min including corrections as per ethnicity)

          -  History of relevant allergy or hypersensitivity (including allergy to the trial
             medication or its excipients)

          -  Unsuitable veins for venipuncture (for instance, veins which are difficult to locate,
             access or puncture, veins with a tendency to rupture during or after puncture) as
             assessed by the investigator

          -  Any finding in the medical examination (including blood pressure (BP), pulse rate
             (PR) or electrocardiogram (ECG) is deviating from normal and judged as clinically
             relevant by the investigator

          -  Any laboratory value outside the reference range that the investigator considers to
             be of clinical relevance; Safety laboratory screening, evaluation can be repeated
             twice during screening.

          -  For healthy volunteers, repeated measurement (i.e. &gt; 2 measurements) of systolic
             blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside
             the range of 50 to 90 mmHg. Volunteers will be excluded with a pulse rate outside the
             range of 45 to 90 bpm.

          -  A marked baseline prolongation of mean QT/QTcF interval (such as QTcF intervals that
             are repeatedly greater than 450 ms in males or repeatedly greater than 470 ms in
             females) or any other relevant ECG finding at screening and prior to randomisation.

          -  A history of additional risk factors for Torsades de Pointes (such as heart failure,
             hypokalemia, or family history of Long QT Syndrome).

          -  Within 10 days prior to administration of trial medication, use of drugs that might
             reasonably influence the results of the trial or that might prolong the QT/QTcF
             interval

          -  Intake of drugs with a long half-life (more than 24hrs) within 30 days or less than
             10 half-lives of the respective drug prior to administration of trial medication

          -  CF and COPD subjects treated with non-permitted concomitant medication

          -  Current or previous participation in another interventional trial, including where an
             investigational drug has been or will be administered within 60 days or 5 half-lives
             (whichever is longer) prior to screening

          -  For healthy volunteers and CF subjects: current smokers or ex-smokers of less than 12
             months and/or with a pack year history of more than 5 years

          -  Further exclusion criteria apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Boehringer Ingelheim Call Center</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gießen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lübeck</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>München-Pasing</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Belfast</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 10, 2017</lastchanged_date>
  <firstreceived_date>November 25, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
